Celgene Corporation

150 px
Type	Public
Traded as	NASDAQ: CELG NASDAQ-100 Component S&P 500 Component
Industry	Biotechnology
Founded	1986
Headquarters	Summit, New Jersey, U.S.
Key people	Sol J. Barer (Chairman) Robert J. Hugin (CEO)
Products	THALOMID REVLIMID
Revenue	US$ 3.626 billion (2010)[1]
Operating income	US$ 989.6 million (2010)[1]
Net income	US$ 880.2 million (2010)[1]
Total assets	US$ 10.177 billion (2010)[1]
Total equity	US$ 5.995 billion (2010)[1]
Employees	4,182 (December 2010)[1]
Website	Celgene.com

Celgene Corporation (NASDAQ: CELG) is an American biotechnology company that manufacturers of drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalomid (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum ("ENL"), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid (lenalidomide), for which the company has received FDA and EMEA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both Thalomid and Revlimid are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS. Celgene also receives royalties from Novartis Pharma AG on sales of the entire Ritalin family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD).

Celgene Cellular Therapeutics, a subsidiary, is a public cord blood bank.

History[link]

In 1986, Celgene, originally a unit of the Celanese Corporation, was spun off as an independent company following the merger of Celanese Corporation with American Hoechst Corporation.

In July 1998, Celgene received approval from the FDA to market Thalamid for the acute treatment of the cutaneous manifestations of moderate to severe ENL.

In April 2000, Celgene reached an agreement with Novartis Pharma AG to license d-MPH, Celgene's chirally pure version of RITALIN. The FDA subsequently granted approval to market d-MPH, or Focalin, in November 2001.

In August 2000, Celgene acquired Signal Pharmaceuticals, Inc., a privately held company that searches for and develops pharmaceuticals that regulate disease-related genes. Signal Pharmaceuticals, Inc. now operates as Celgene Research San Diego, a wholly owned subsidiary of Celgene Corporation.

In December 2002, Celgene acquired Anthrogenesis, a privately held New Jersey-based biotherapeutics company and cord blood banking business, which is developing technology for the recovery of stem cells from placental tissues following the completion of full-term successful pregnancies. Anthrogenesis now operates as Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene.

In December 2005, Celgene received approval from the FDA to market Revlimid for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

In May 2006, Celgene received approval for Thalamid in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.

In June 2007, Celgene received full marketing authorization for Revlimid in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy by the European Commission.

In March 2008, Celgene closed its $2.9 billion acquisition of Pharmion Corporation.

In December 2009, Celgene announced the acquisition of Gloucester Pharmaceuticals.^[2]

In June 2010 Celgene Corporation and Abraxis BioScience Inc. jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. ^[3]

In 2010 Celgene looked to relocate its UK Head Quarters from Riverside House in Windsor to a new development Stockley Park, Uxbridge.^[4]

In January 2012, Celgene and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced a definitive merger agreement under which Celgene Corporation will acquire Avila Therapeutics, Inc. Under the terms of the merger agreement, Celgene will acquire Avila Therapeutics, Inc. for $350 million in cash, plus up to $195 million for milestones contingent upon the development and regulatory approval of AVL-292, as well as up to $380 million in potential milestone payments contingent upon the development and approval of candidates generated from the Avilomics platform. ^[5]

Products[link]

References[link]

External links[link]

• Official website

Companies portal

v t e Companies of the NASDAQ-100 index Activision Blizzard Adobe Akamai Alexion Pharmaceuticals Altera Amazon.com Amgen Apollo Group Apple Applied Materials Autodesk ADP Avago Baidu Bed Bath & Beyond Biogen Idec BMC Software Broadcom C.H. Robinson CA Technologies Celgene Cerner Check Point Cisco Citrix Cognizant Comcast Costco Ctrip Dell Dentsply DirecTV Dollar Tree eBay Electronic Arts Expedia Expeditors International Express Scripts F5 Networks Fastenal Fiserv Flextronics Fossil Garmin Gilead Sciences Google Green Mountain Coffee Roasters Henry Schein Infosys Intel Intuit Intuitive Surgical KLA Tencor Lam Research Liberty Interactive Life Technologies Linear Technology Marvell Mattel Maxim Integrated Products Microchip Technology Micron Technology Microsoft Monster Beverage Mylan NetApp Netflix News Corporation Nuance Communications Nvidia O'Reilly Auto Parts Oracle Paccar Paychex Perrigo Priceline.com Qualcomm Randgold Resources Research In Motion Ross Stores SanDisk Seagate Sears Sigma-Aldrich Sirius XM Radio Staples Starbucks Stericycle Symantec Teva Pharmaceutical Texas Instruments Verisign Vertex Pharmaceuticals Virgin Media Vodafone Warner Chilcott Whole Foods Market Wynn Resorts Xilinx Yahoo!